Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0273202 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Francesco Vladimiro Segala und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Sicurezza e Bioetica-Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: COVID-19, Respiratory Insufficiency. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death. In case of suPAR testing unavailability, the Severe COvid Prediction Estimate (SCOPE) score may be used as an alternative in guiding treatment decisions.
Methods
We conducted a monocenter, retrospective cohort study, including patients with SARS-CoV2 infection and respiratory failure. Patients treated with anakinra (anakinra group, AG) were compared to two control groups of patients who did not receive anakinra, respectively with ≥ 6 ng/mL (CG1) and < 6 ng/mL (CG2) baseline suPAR levels. Controls were manually paired by age, sex, date of admission and vaccination status and, for patients with high baseline suPAR, propensity score weighting for receiving anakinra was applied. Primary endpoint of the study was disease progression at day 14 from admission, as defined by patient distribution on a simplified version of the 11-point World Health Organization Clinical Progression Scale (WHO-CPS).
Results
Between July, 2021 and January, 2022, 153 patients were included, among which 56 were treated with off-label anakinra, 49 retrospectively fulfilled prescriptive criteria for anakinra and were assigned to CG1, and 48 presented with suPAR levels < 6ng/mL and were assigned to CG2. At day 14, when comparing to CG1, patients who received anakinra had significantly reduced odds of progressing towards worse clinical outcome both in ordinal regression analysis (OR 0.25, 95% CI 0.11–0.54, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dipartimento di Sicurezza e Bioetica-Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.
- Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
ORCID-Profile: Francesco Vladimiro Segala, Emanuele Rando, Marcantonio Negri, Evangelos J Giamarellos-Bourboulis
Zitieren
APA
Segala, F. V., Rando, E., Salvati, F., Negri, M., Catania, F., Sanmartin, F., Murri, R., Giamarellos-Bourboulis, E. J., & Fantoni, M. (2023). Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0273202
Vancouver
Segala FV, Rando E, Salvati F, Negri M, Catania F, Sanmartin F, et al. Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study. PLOS ONE. 2023. doi:10.1371/journal.pone.0273202
BibTeX
@article{Segala2023,
author = {Segala, Francesco Vladimiro and Rando, Emanuele and Salvati, Federica and Negri, Marcantonio and Catania, Francesca and Sanmartin, Flavia and Murri, Rita and Giamarellos-Bourboulis, Evangelos J and Fantoni, Massimo},
title = {Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0273202}
}
EUVIMED